Hepatitis Delta Virus Infection: An Overview

Hepatitis Delta Virus (HDV) Infection: An Overview

Structured Medical Education Summary

1. Main Clinical Topics Discussed

• Global and regional epidemiology of Hepatitis Delta Virus (HDV) infection among Hepatitis B Virus (HBV) carriers
• HDV prevalence data from underreported regions, particularly former Soviet Union countries and Central Asia
• HDV pathophysiology and viral replication mechanisms
• Current and emerging therapeutic strategies for chronic HDV infection

2. Key Learning Points, Guidelines, and Recommendations

Epidemiology & Disease Burden

• HDV is a defective RNA virus — the smallest known human pathogenic RNA virus — requiring HBsAg for replication and transmission
• High-prevalence zones include: Mongolia, Pakistan, Central African Republic, western Amazon basin, and Kiribati Islands
• Significant data gaps exist across former Soviet Union countries; many are marked "no data" on global prevalence maps
• Two major endemic zones identified in Eastern Europe: Romania and Moldova
• HDV is both a demographic and social problem, disproportionately affecting young, economically active individuals aged 20–50 years

Vaccination Impact

• Universal HBV vaccination programs have led to a 10-fold reduction in acute hepatitis B incidence over the past 20 years
• However, paradoxically, improved detection strategies in some regions (e.g., Kazakhstan) have revealed *increasing* diagnosed HDV case numbers despite declining HBV prevalence

Current Treatment Guidelines

• Guidelines from AASLD, APASL, and EASL recommend pegylated interferon-alpha (PEG-IFN-α) for 12 months (possibly longer) as the only approved treatment option
• Limitations of PEG-IFN-α include:

- Sustained virological response (SVR) rates of only 0–47%

- Treatment duration of 48–96 weeks

- Poor tolerability with significant side effects (cytopenias, flu-like symptoms)

- High long-term relapse rates

3. Specific Clinical Data, Statistics, and Study Results

Regional Prevalence Data

• Russia: Eastern regions show HDV prevalence of 21–60% among HBV carriers (Chukotka: 30–31%; Sakha: 24.5–31%; Tuva: 22.6%); western cities lower (Moscow: 19.5%; Samara: 39%; Astrakhan: 10%)
• Moldova (population 3.5M): Lifetime infection risk 20–60%; ~1,700 new HBsAg carriers, ~3,000 deaths, and ~200 disability cases annually; 2012 incidence of acute hepatitis D: 0.15 per 100,000
• Georgia: HBsAg positivity ~2.9% in adults; only 0.9% of HBsAg-positive individuals co-infected with HDV
• Azerbaijan (multicenter study, n=2,169 chronic HBV patients over 10 years): HDV co-infection detected in ~12%; at first admission: compensated cirrhosis 32%, hepatic decompensation episodes 27%, hepatocellular carcinoma (HCC) 2.3%
• Uzbekistan (2019): Anti-HDV positivity: Tashkent 12%, Termez 14%
• Moldova: 70–80% of HDV-infected individuals are unaware of their HBV/HDV status; only 1 in 4 diagnosed at late fibrosis stages (F3–F4)

Emerging Therapies — Trial Data

• Bulevirtide (HBV/HDV entry inhibitor, NTCP receptor inhibitor): Identified as safe and promising monotherapy; combination with PEG-IFN-α may induce functional cure; currently approved and in use in Russia; cost is significant (~dollars per month)
• Interferon Lambda (Phase 2 RCT, n=33):

- High-dose cohort (180 mcg/week × 48 weeks): durable biological response in 36%

- Low-dose cohort (120 mcg/week): response